BusinessXeris Pharmaceuticals Achieves Phase 3 Milestones of its Ready-to-Use Glucagon Rescue Pen for the Treatment of Severe HypoglycemiaBy Nasdaq OMXFeb 15, 2018, 10:00 PM UTC
BusinessFDA Grants Orphan Drug Designation (ODD) for Xeris Pharmaceuticals' Ready-to-Use Glucagon for the Treatment of Hyperinsulinemic Hypoglycemia (HH). Results from Phase 2a Study in Post-Bariatric Hypoglycemia, Associated with HH, Published.By Nasdaq OMXFeb 8, 2018, 11:30 PM UTC
BusinessXOMA Reports Third Quarter 2016 Achievements and Financial ResultsBy Nasdaq OMXNov 9, 2016, 2:00 PM UTC
BusinessXOMA Announces Significant Step Toward Initiating Pediatric Phase 2 Clinical Study for XOMA 358 in Children with Congenital HyperinsulinismBy Nasdaq OMXOct 19, 2016, 1:01 PM UTC
BusinessXOMA Provides Update from Ongoing Phase 2 XOMA 358 Clinical StudiesBy Nasdaq OMXSep 15, 2016, 11:26 PM UTC
BusinessXOMA Presented First Data from Novel Antibody Fragment to Address Severe Acute Hypoglycemia at the ENDO MeetingBy Nasdaq OMXApr 4, 2016, 1:00 PM UTC
BusinessXOMA Reports Fourth Quarter and Full-Year 2015 Financial ResultsBy Nasdaq OMXMar 9, 2016, 9:01 PM UTC
BusinessXeris Pharmaceuticals, Inc. to Present G-Pen Human Factors Study Results at 2016 ATTD MeetingBy Nasdaq OMXFeb 4, 2016, 3:22 PM UTC
